| Title |
Targeting the hypoxia pathway to treat pancreatic cancer
|
|---|---|
| Published in |
Drug Design, Development and Therapy, April 2015
|
| DOI | 10.2147/dddt.s80888 |
| Pubmed ID | |
| Authors |
Lori A Erickson, W Edward Highsmith, Peiwen Fei, Jun Zhang |
| Abstract |
The correlation between hypoxia and pancreatic cancer has long been discussed. Hao's research team made many efforts on revealing the oncogenic function of hypoxic inducible factor-1 (HIF-1) in pancreatic cancer progression and development in recent years. Based on their research, they linked micro-environmental regulation of pancreatic cancer and its clinical significance. Hao's research team suggests it is a promising approach to target HIF-1 for the management of pancreatic cancer progression and invasion. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 24% |
| Researcher | 5 | 20% |
| Student > Master | 4 | 16% |
| Student > Bachelor | 2 | 8% |
| Other | 2 | 8% |
| Other | 2 | 8% |
| Unknown | 4 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 7 | 28% |
| Agricultural and Biological Sciences | 4 | 16% |
| Medicine and Dentistry | 4 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 12% |
| Computer Science | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 4 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 April 2015.
All research outputs
#22,759,802
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#1,754
of 2,268 outputs
Outputs of similar age
#240,617
of 279,170 outputs
Outputs of similar age from Drug Design, Development and Therapy
#61
of 83 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,170 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.